Bruker price target lowered to $69 from $75 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on Bruker (BRKR) to $69 from $75 and keeps an Overweight rating on the shares. The company reported a tough print in a tough macro environment, the analyst tells investors in a research note. The firm is “right-sizing” estimates on the lower fiscal 2024 targets, but remains confident that the business is positioned favorably across multi-omics and materials sciences that Bruker should benefit from the demand recovery in biopharma and China.